Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maarten L. Janmaat
Observed names:
Janmaat, M.L.,
M L Janmaat,
M. Janmaat,
M. L. Janmaat,
M.L. Janmaat,
Maarten JANMAAT,
Maarten Janmaat,
Maarten L Janmaat
show all 8
Institutions:
MorphoSys (Germany),
The Netherlands Cancer Institute,
Genmab (Netherlands)
Observed institutions:
MorphoSys (Germany),
University of Dundee,
Amsterdam UMC Location University of Amsterdam,
The Netherlands Cancer Institute,
Genmab (Netherlands),
The Christie Hospital,
Amsterdam UMC Location Vrije Universiteit Amsterdam
show all 7
ORCID:
0000-0003-4980-730X
Observed ORCID:
0000-0003-4980-730X
OpenAlex ID:
A5042768703
Bispecific antibodies: a mechanistic review of the pipeline
2019
·
Aran F. Labrijn
, Maarten L. Janmaat
, et al.
·
Nature Reviews Drug Discovery
·
1,371
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
2016
·
Niels W. C. J. van de Donk
, Maarten L. Janmaat
, et al.
·
Immunological Reviews
·
362
PDF
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
2003
·
Maarten L Janmaat
, Frank A E Kruyt
, et al.
·
PubMed
·
327
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
2018
·
Julia Boshuizen
, Louise A Koopman
, et al.
·
Nature Medicine
·
238
Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients
2006
·
Maarten L. Janmaat
, Mariëlle I. Gallegos-Ruiz
, et al.
·
Journal of Clinical Oncology
·
218
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cells
2005
·
Maarten L. Janmaat
, José A. Rodriguez
, et al.
·
International Journal of Cancer
·
151
Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling
2005
·
Maarten L Janmaat
, José A Rodriguez
, et al.
·
Molecular Pharmacology
·
114
Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
2003
·
Maarten L. Janmaat
, Giuseppe Giaccone
·
The Oncologist
·
84
PDF
The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
2003
·
M L Janmaat
, G Giaccone
·
PubMed
·
76
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
2021
·
Julia Boshuizen
, Nora Pencheva
, et al.
·
Cancer Research
·
74
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
2019
·
Louise A. Koopman
, Mikkel G. Terp
, et al.
·
JCI Insight
·
60
PDF
Erythropoietin accelerates smooth muscle cell–rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release
2009
·
Maarten L. Janmaat
, Jasper L. T. Heerkens
, et al.
·
Blood
·
57
Evidence that the dephosphorylation of Ser535 in the ∊-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for the activation of eIF2B by insulin
2002
·
Xuemin WANG
, Maarten JANMAAT
, et al.
·
Biochemical Journal
·
46
PDF
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels
2007
·
Marcel N.A. Bijman
, Cristian A. Hermelink
, et al.
·
Biochemical Pharmacology
·
39
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
2023
·
Ida H. Hiemstra
, Kim C.M. Santegoets
, et al.
·
EBioMedicine
·
33
PDF
Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines
2009
·
Marcel N.A. Bijman
, Maria P.A. van Berkel
, et al.
·
Anti-Cancer Drugs
·
32
A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer
2005
·
G. Giaccone
, T. Lechevalier
, et al.
·
Journal of Clinical Oncology
·
26
Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
2019
·
Bart ECG De Goeij
, Maarten L Janmaat
, et al.
·
Blood
·
20
Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys
2017
·
Mario Losen
, Aran F. Labrijn
, et al.
·
Scientific Reports
·
14
PDF
Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.
2015
·
Esther CW Breij
, Sandra Verploegen
, et al.
·
Journal of Clinical Oncology
·
10
Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC
2018
·
Louise A. Koopman
, Maarten L. Janmaat
, et al.
·
Cancer Research
·
9
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models
2022
·
Kristel Kemper
, Ellis Gielen
, et al.
·
Life Science Alliance
·
8
PDF
Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies
2022
·
Simone C. Oostindie
, Mir Farshid Alemdehy
, et al.
·
Blood
·
6
Basic Fibroblast Growth Factor-Mediated Overexpression of Vascular Endothelial Growth Factor in 1F6 Human Melanoma Cells is Regulated by Activation of PI-3K and p38 MAPK
2009
·
Dennis Fontijn
, Linda J. W. Bosch
, et al.
·
Analytical Cellular Pathology
·
6
P-485 EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer
2005
·
G. Giaccone
, M. Janmaat
, et al.
·
Lung Cancer
·
3
Show more works
View as search
Works count:
44
Citation count:
3,388
H-index:
18
I10-index:
20
Year
Topic
Type
